Journal of Clinical Pediatrics ›› 2019, Vol. 37 ›› Issue (4): 312-.doi: 10.3969/j.issn.1000-3606.2019.04.017

Previous Articles     Next Articles

TCRαβ T cell/B cell-depleted hematopoietic stem cell transplantation for primary immunodeficiency

Reviewer:XU Qiling, AN Yunfei, Reviser: ZHAO Xiaodong   

  1. Department of Rheumatology and Immunology, Children’s Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Coporation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Child Infection and Immunity, Chongqing 400014, China
  • Online:2019-04-15 Published:2019-04-18

Abstract: Primary immunodeficiency disease (PID) is a rare monogenic hereditary disease with severe clinical manifestations and high mortality. Early diagnosis and complete immune reconstitution in a timely and effective manner is the key to prognosis. Nowadays, gene therapy is still in the experimental stage, and hematopoietic stem cell transplantation is currently the only means of reconstructing immunity. TCRαβ T cell/B cell-depleted hematopoietic stem cell transplantation as a novel T-cell-free transplantation strategy has been gradually used in the radical treatment of primary immunodeficiency disease in children in recent years. It has achieved satisfactory results in the prevention and control of graft-versus-host disease and the reduction of post-transplant infection. This article reviews its biological basis and recent progress.

Key words:  primary immunodeficiency disease; TCRαβ T cell/B cell-depletion; γδ T cell; hematopoietic stem cell transplantation; graft-versus-host disease; treatment